Zealand Pharma’s stock drops sharply after trial data raises potential side effect risks for its experimental obesity treatment.
Zealand Pharma (ZLDPF) shares fell as much as 26% after new data from its experimental weight-loss drug, survodutide, raised safety concerns. The Danish biopharmaceutical company reported the drug met efficacy targets but sparked investor worries over possible side effects.
The decline follows the release of trial results, which highlighted adverse events that overshadowed positive outcomes. Prior to the data, Zealand Pharma had been trading higher on optimism surrounding its obesity drug pipeline, competing with established players like Novo Nordisk and Eli Lilly.
Markets reacted swiftly to the news, with the stock erasing recent gains and trading near session lows. Analysts noted the sell-off reflected broader caution over drug safety profiles in the weight-loss treatment sector.